undamentalytics Newsletter
Sign in

Precigen, Inc. (PGEN) stock

Add to watchlist

Add holding +

NASDAQ: PGEN Nasdaq Biotechnology Next results ~November 4, 2026

Precigen, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: data-quality checks not passed.

Price vs value

Under review: data-quality checks not passed. We'll show the comparison once resolved.

Precigen, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders1 buying, 7 selling1 purchase and 40 sales by directors and officers, last 12 monthsInsider trades
  • Funds120 adding, 74 cuttingOf 33 active managers that changed their stake, 15 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Precigen files

Where Precigen stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $22m, up 43.1% on a year earlier, faster than the 42.2% growth a quarter earlier. Free-cash-flow margin rose to -340.4% from -426.0% a year earlier. Operating margin widened to -83.9% from -183.8%. The diluted share count is up 23.3% on a year earlier, which dilutes existing holders. It passes 2 of our 6 financial-health checks.

Our model value for Precigen is under review, so past values are not shown until it is resolved.

Source: 10-Q filed August 4, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 4, 2026 (estimated)

Current signal Net margin expanding: TTM net margin reached 100.2%, up 694.0pp year over year.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 43.1% over the last 12 months.
  • Margins widening. Operating margin is up 99.9 points on a year ago.
  • Estimates rising. Analysts' consensus for next year's earnings per share has risen 210.9% over 90 days.

Things to watch

  • Results due soon. Results are expected around 12 November; the share price can move sharply on the day.
  • Loss-making. Operating margin is -83.9%: costs exceed revenue.
  • Burning cash. Free cash flow was -340.4% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 43.7% of revenue: a real cost that cash-flow figures leave out.
  • Share dilution. Diluted shares rose 23.3% in a year.
  • High debt. Long-term debt exceeds cash by $0.1bn, more than 1.5 times annual revenue.

Latest results: FY2026 Q2

Filed August 4, 2026
Earnings per share
$0.05 against an average estimate of -$0.01: beat by 475.1%
Revenue
$55m, up 6322.7% on a year earlier
Share reaction
+4.2% in the first session after the results on August 4, 2026, against +1.6% for the S&P 500
Next report
November 4, 2026

Precigen's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-25.9%
  • 1 week-14.9%
  • 1 month-39.8%
  • This year+23.0%
  • 1 year+24.2%
  • 5 years-6.5%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

EPS (TTM, diluted)
$-0.44

Growth

Share count change
+23.3%

Cash

Free cash flow (TTM)
-$115M

Earnings

Last results
August 4, 2026
Next results (est.)
November 12, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Insider trade
  2. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Precigen, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: data-quality checks not passed.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Precigen, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.6%: the 10-year Treasury yield (4.9%) plus a beta of 1.04 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. — Does not apply: This model is withheld pending its input or assumption review.
Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$7.7 ~$7.3–$15 Included
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: This model is withheld pending its input or assumption review.
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: This model is withheld pending its input or assumption review.
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. — Does not apply: This model is withheld pending its input or assumption review.
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: This model is withheld pending its input or assumption review.
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Precigen, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20152016201720182019202020212022202320242025
Share price$29.88$24.08$11.52$6.54$5.48$10.20$3.71$1.52$1.34$1.12$4.18
Market value$3.3bn$2.8bn$1.4bn$847m$845m$1.7bn$734m$305m$328m$300m$1.3bn
+ Net debt (− = net cash)−$127m−$54m−$60m$115m$154m$152m$167m$82m−$8m−$30m$70m
Enterprise value$3.2bn$2.8bn$1.3bn$962m$999m$1.9bn$901m$386m$320m$270m$1.4bn
Multiples
Price / sales 19.1x14.9x6.0x5.6x9.3x53.3x51.4x11.3x52.6x76.4x135.1x
Price / earnings ———————10.8x———
Price / free cash flow 144.8x——————————
EV / EBITDA ———————————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

9 /100

Weak moat

How hard Precigen's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -52.2% of total assets over 10 years.

  • Durability 10 / 20

    Operating margin has been a median -97.3%; its worst year was -545.6%.

  • Cash conversion 1 / 20

    Free cash flow was positive in 1 of 10 years, at a median -98.1% of revenue.

  • Discipline 0 / 20

    The diluted share count rose 94.1% over five years; stock-based pay has been a median 21.8% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (14 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 4, 2026, after the close. Analysts expect revenue of $72m for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $0.22 +116% $236m +2335%
Next $0.62 +189% $437m +85%

Next year's EPS estimate has moved +210.9% in 90 days, across 4 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −817.4% on 90 days ago. In the last 30 days, 0 analysts raised Precigen, Inc.'s forecast and 0 cut it.

Consensus EPS forecast Precigen, Inc., last 90 days
−$0.20 $0.00 $0.20 $0.40 $0.60 $0.80 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$0.03 Current fiscal year, 60 days ago: $0.22 Current fiscal year, 30 days ago: $0.22 Current fiscal year, 7 days ago: $0.22 Current fiscal year, Now: $0.22 $0.22 Next fiscal year, 90 days ago: $0.20 Next fiscal year, 60 days ago: $0.68 Next fiscal year, 30 days ago: $0.63 Next fiscal year, 7 days ago: $0.63 Next fiscal year, Now: $0.62 $0.62

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$0.03$0.20
60 days ago $0.22$0.68
30 days ago $0.22$0.63
7 days ago $0.22$0.63
Now $0.22$0.62

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.01 $0.05 +475.1%
Mar 2026 −$0.04 −$0.02 +50.0%
Dec 2025 −$0.08 −$0.01 +88.1%
Sept 2025 −$0.10 −$1.06 −1015.8%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

4 analysts, Oct 2026
Buy375%
Hold125%
Sell00%

Monthly trend

  1. Oct 20261214
  2. Sep 20261214
  3. Aug 20261113
  4. Jul 20261113

Counts of recommendations published by analysts covering Precigen, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
23.8%
of tradable shares
Days to cover
8.53
at average volume
Short interest, 1 month
+10%
to October 15, 2026
Held by institutions
73%
of shares
Held by insiders
12.6%
of shares
Employees
160
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
PGEN−64%−59%−12%−16%+273%+23%
Industry peers (median)−35%−56%−18%−29%−5%−27%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
PGEN17%33%42%50%67%73%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
PGEN−68%−71%−60%−64%−42%−41%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 3, 2015: 98% from November 10, 2015 to December 16, 2024. Getting back needed a 6231% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$3.10 – $8.56
From 52-week high
−40.0%
vs 50-day average
−28.4%
vs 200-day average
−2.6%
Volatility (1 year)
83%
Beta vs S&P 500
1.41

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
7 up, 5 down
typical move ±9.9%
After a week
6 up, 6 down
typical move ±7.0%
After a month
5 up, 7 down
typical move ±14.8%
Results releasedNext dayS&P 500 next day5 days21 days
August 4, 2026 +4.2% +1.6% +3.8% +6.1%
May 13, 2026 +12.7% +1.4% +4.7% +9.1%
March 25, 2026 +24.3% −1.2% +25.6% +31.9%
November 13, 2025 +20.6% −1.7% −3.0% −5.2%
May 14, 2025 −3.0% +0.6% −2.2% +12.6%
March 19, 2025 +7.8% +0.8% −3.6% −16.8%
November 14, 2024 −10.9% −1.9% −2.2% −27.2%
August 14, 2024 −1.8% +2.0% +9.2% −3.7%
August 6, 2024 −9.9% +0.2% −16.8% −26.7%
May 14, 2024 +6.7% +1.7% +3.0% +25.9%
March 19, 2024 +3.6% +1.5% +0.7% −5.0%
November 9, 2023 −13.5% +0.8% −8.7% −7.9%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Revenue (TTM) Precigen, Inc.
$0 $50M $100M $150M FY20 Q3 FY21 Q2 FY22 Q1 FY23 Q2 Revenue (TTM), FY20 Q3: $100.8M Revenue (TTM), FY20 Q4: $103.2M Revenue (TTM), FY21 Q1: $97.9M Revenue (TTM), FY21 Q2: $71.2M Revenue (TTM), FY21 Q3: $51M Revenue (TTM), FY21 Q4: $35.3M Revenue (TTM), FY22 Q1: $16.3M Revenue (TTM), FY22 Q2: $15.4M Revenue (TTM), FY22 Q3: $28.8M Revenue (TTM), FY22 Q4: $26.9M Revenue (TTM), FY23 Q1: $23.2M Revenue (TTM), FY23 Q2: $22.1M $22.1M

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Revenue (TTM)
FY20 Q3 $100.8M
FY20 Q4 $103.2M
FY21 Q1 $97.9M
FY21 Q2 $71.2M
FY21 Q3 $51M
FY21 Q4 $35.3M
FY22 Q1 $16.3M
FY22 Q2 $15.4M
FY22 Q3 $28.8M
FY22 Q4 $26.9M
FY23 Q1 $23.2M
FY23 Q2 $22.1M
Revenue growth, TTM YoY Precigen, Inc.
-100% -50% 0% 50% FY20 Q3 FY21 Q2 FY22 Q1 FY23 Q2 Revenue growth, TTM YoY, FY20 Q3: -12.2% Revenue growth, TTM YoY, FY20 Q4: 13.7% Revenue growth, TTM YoY, FY21 Q1: -0.1% Revenue growth, TTM YoY, FY21 Q2: -25.5% Revenue growth, TTM YoY, FY21 Q3: -49.4% Revenue growth, TTM YoY, FY21 Q4: -65.7% Revenue growth, TTM YoY, FY22 Q1: -83.3% Revenue growth, TTM YoY, FY22 Q2: -78.3% Revenue growth, TTM YoY, FY22 Q3: -43.5% Revenue growth, TTM YoY, FY22 Q4: -23.9% Revenue growth, TTM YoY, FY23 Q1: 42.2% Revenue growth, TTM YoY, FY23 Q2: 43.1% 43.1%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Revenue growth, TTM YoY
FY20 Q3 -12.2%
FY20 Q4 13.7%
FY21 Q1 -0.1%
FY21 Q2 -25.5%
FY21 Q3 -49.4%
FY21 Q4 -65.7%
FY22 Q1 -83.3%
FY22 Q2 -78.3%
FY22 Q3 -43.5%
FY22 Q4 -23.9%
FY23 Q1 42.2%
FY23 Q2 43.1%
Operating margin (TTM) Precigen, Inc.
-400% -300% -200% -100% 0% FY18 Q1 FY18 Q4 FY19 Q3 FY20 Q4 Operating margin (TTM), FY18 Q1: -69.3% Operating margin (TTM), FY18 Q2: -73.1% Operating margin (TTM), FY18 Q3: -86.6% Operating margin (TTM), FY18 Q4: -266.9% Operating margin (TTM), FY19 Q1: -295.1% Operating margin (TTM), FY19 Q2: -307.7% Operating margin (TTM), FY19 Q3: -318.7% Operating margin (TTM), FY19 Q4: -183.8% Operating margin (TTM), FY20 Q1: -144.5% Operating margin (TTM), FY20 Q2: -138.0% Operating margin (TTM), FY20 Q3: -119.2% Operating margin (TTM), FY20 Q4: -83.9% -83.9%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Operating margin (TTM)
FY18 Q1 -69.3%
FY18 Q2 -73.1%
FY18 Q3 -86.6%
FY18 Q4 -266.9%
FY19 Q1 -295.1%
FY19 Q2 -307.7%
FY19 Q3 -318.7%
FY19 Q4 -183.8%
FY20 Q1 -144.5%
FY20 Q2 -138.0%
FY20 Q3 -119.2%
FY20 Q4 -83.9%
FCF margin (TTM) Precigen, Inc.
-600% -400% -200% 0% FY20 Q3 FY21 Q2 FY22 Q1 FY23 Q2 FCF margin (TTM), FY20 Q3: -102.6% FCF margin (TTM), FY20 Q4: -81.9% FCF margin (TTM), FY21 Q1: -72.6% FCF margin (TTM), FY21 Q2: -90.3% FCF margin (TTM), FY21 Q3: -124.7% FCF margin (TTM), FY21 Q4: -178.3% FCF margin (TTM), FY22 Q1: -403.7% FCF margin (TTM), FY22 Q2: -426.0% FCF margin (TTM), FY22 Q3: -249.3% FCF margin (TTM), FY22 Q4: -260.0% FCF margin (TTM), FY23 Q1: -293.2% FCF margin (TTM), FY23 Q2: -340.4% -340.4%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period FCF margin (TTM)
FY20 Q3 -102.6%
FY20 Q4 -81.9%
FY21 Q1 -72.6%
FY21 Q2 -90.3%
FY21 Q3 -124.7%
FY21 Q4 -178.3%
FY22 Q1 -403.7%
FY22 Q2 -426.0%
FY22 Q3 -249.3%
FY22 Q4 -260.0%
FY23 Q1 -293.2%
FY23 Q2 -340.4%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2011 Dec 2011 2012 Dec 2012 2013 Dec 2013 2014 Dec 2014 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025
Income
Revenue 8 14 24 72 174 191 231 151 91 32 14 27 6 4 10
EBITDA −78 −67 −51 −60 −129 −101 −107 −472 — — — — −93 −131 −107
Operating income −82 −75 −58 −70 −147 −125 −138 −506 — — — — −100 −135 −111
Net income −85 −82 −39 −82 −84 −187 −117 −509 −322 −171 −92 28 −96 −126 −251
Diluted EPS −$18.92 −$18.77 −$1.40 −$0.83 −$0.76 −$1.58 −$0.98 −$3.93 −$2.09 −$1.02 −$0.47 $0.14 −$0.39 −$0.47 −$1.37
Growth (year on year)
Revenue — +71.9% +72.5% +202.7% +141.4% +10.0% +21.0% −34.5% −40.0% −64.7% −55.4% +88.6% −76.9% −36.9% +146.7%
Net income — — — — — — — — — — — — −438.7% — —
Diluted EPS — — — — — — — — — — — — −378.6% — —
Margins
EBITDA margin −974.5% −487.7% −213.9% −82.8% −74.4% −52.7% −46.2% −312.5% — — — — <−999% <−999% <−999%
Operating margin <−999% −545.6% −244.2% −97.3% −84.6% −65.6% −59.7% −334.4% — — — — <−999% <−999% <−999%
Net margin <−999% −594.4% −164.1% −113.8% −48.7% −97.7% −50.7% −336.9% −355.3% −533.0% −646.0% 105.2% <−999% <−999% <−999%
Free-cash-flow margin <−999% −501.1% −232.4% −36.5% 13.2% −42.2% −65.1% −109.7% −191.6% −264.3% −441.7% −260.0% <−999% <−999% −927.6%
Cash flow
Cash from operations −82 −62 −54 −20 36 −49 −104 −124 −136 −77 −56 −65 −67 −68 −88
Capital spending 13 7 2 6 13 32 47 42 38 8 7 5 2 9 2
Free cash flow −95 −69 −55 −26 23 −81 −150 −166 −174 −85 −63 −70 −68 −77 −90
Stock-based pay 1 1 3 22 39 42 42 36 19 18 14 10 10 9 11
Free cash flow after stock pay −96 −70 −58 −48 −16 −123 −192 −202 −193 −103 −77 −80 −78 −86 −101
Balance sheet
Cash 20 10 50 27 136 63 68 97 66 52 36 5 8 30 30
Total debt 0 0 2 13 9 9 8 212 220 204 203 86 — 0 100
Net debt (negative = net cash) −20 −10 −48 −15 −127 −54 −60 115 154 152 167 82 −8 −30 70
Diluted shares 5m 6m 41m 99m 111m 118m 120m 130m 154m 167m 198m 200m 245m 268m 313m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 6 checks passed · June 30, 2026
What it owns · $170m
Short-term assets $134mLonger-term assets $36m
What it owes, and who funded it · $170m
Short-term liabilities $29mLonger-term liabilities $97mShareholders' equity $44m
  • Short-term assets cover short-term liabilities $134m of assets due within a year against $29m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $134m short-term assets against $97m of longer-dated liabilities.
  • More cash than debt $16m of cash against $94m of debt.
  • Debt below 40% of shareholders' equity Debt is 215% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 168% to 215% over five years.
  • A year's operating cash flow covers at least 20% of debt −$114m of operating cash flow against $94m of debt.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Precigen, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+23.3%
year over year

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated PGEN JANX CRSP SCYX ABEO CELU Median
Revenue, last 12 months $22m $24m $25m $19m $26m $19m $55m
Revenue growth, last 12 months 43.1% >999% −34.3% 489.8% −87.7% −58.1% 12.7%
Revenue growth, 3-year average −38.6% 45.7% −47.1% −47.9% 212.0% 7.2% 13.1%
Revenue growth, latest quarter >999% >999% >999% −82.8% >999% −5.3% 10.2%
Gross margin — — — 26.0% 67.1% 19.2% 82.9%
Operating margin −83.9% −598.1% <−999% −117.6% −327.6% −264.3% −187.2%
Operating margin, 3-year average −178.2% <−999% <−999% −592.1% <−999% −204.2% −361.6%
Net margin 100.2% −427.5% <−999% −53.3% −246.4% −245.7% −163.5%
Cash from operations / revenue −331.9% −171.9% <−999% −69.3% −299.5% −47.8% −168.8%
Free-cash-flow margin −340.4% −174.7% <−999% −69.3% −319.5% −80.1% −168.1%
Free-cash-flow margin, 3-year average −285.6% <−999% −793.9% −304.8% <−999% −50.3% −306.5%
Stock pay / revenue 43.7% 153.7% 276.8% 12.3% 45.4% 66.5% 20.7%
Change in share count 23.3% 6.2% 10.0% 1.9% 36.6% 24.7% 8.3%

Median of all 185 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue YoY
Product and Service $7.9M ▲ 100.4%
Products $4M ▲ 841.9%
Services $3.9M ▲ 11.1%
Service Exemplar $3.9M ▲ 11.1%
Papzimeos $3.4M —
Product Exemplar $562,000 ▲ 33.2%

These categories overlap or exclude eliminations, so shares aren't shown.

From Precigen, Inc.'s 10-K filed March 25, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$798M
Institutions reporting
209
Shares held vs prior quarter
▲ 5.0%
Positions opened / closed
35 / 28

Top buyers and sellers, Q2 2026: 120 institutions bought and 74 sold ; the biggest buyer was Diametric Capital, LP (+2.5M shares) and the biggest seller Point72 Asset Management, L.P (−5.4M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Patient Capital Management, LLC $109M 19.0M 13.6% ▲ 6.8%
Blackrock, Inc. $97.7M 17.1M 12.2% ▲ 12.6%
State Street Corp $68.4M 12.0M 8.6% ▲ 10.2%
Diametric Capital, LP $52.8M 9.3M 6.6% ▲ 36.3%
Vanguard Capital Management LLC $45.1M 7.9M 5.6% ▲ 10.6%
Tang Capital Management LLC $36.6M 6.4M 4.6% 0.0%
Boxer Capital Management, LLC $29.4M 5.2M 3.7% ▲ 47.1%
Geode Capital Management, LLC $28.6M 5.0M 3.6% ▲ 8.8%
Iridian Asset Management LLC $23M 4.0M 2.9% ▲ 12.2%
Morgan Stanley $19.8M 3.5M 2.5% ▲ 43.7%
Occam Crest Management LP $19.7M 3.6M 2.5% ▼ 15.5%
Goldman Sachs Group Inc $19.4M 3.4M 2.4% ▲ 1.7%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Precigen, Inc.'s complete shareholder register. Values are as reported by the filers ; 1 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $24,662 1 trade by 1 insider, last 12 months Insider sales History → $44.6M 40 trades by 7 insiders · 12% under pre-set plans
Net ▼ $44.5M net selling
Insider Date Trade Shares Price Value
Kindler Jeffrey B Director August 26, 2026 Sell 185,000 $7.44 $1.4M
Tennant Phil Chief Commercial Officer August 25, 2026 Sell pre-set plan 79,166 $7.50 $593,745
Shah Rutul R Chief Operating Officer August 25, 2026 Sell pre-set plan 15,342 $7.50 $115,065
Shah Rutul R Chief Operating Officer August 21, 2026 Sell pre-set plan 34,658 $7.50 $259,935
Agee Nancy H Director August 21, 2026 Buy 3,411 $7.23 $24,662
Shah Rutul R Chief Operating Officer August 6, 2026 Sell pre-set plan 32,739 $6.86 $224,590
Shah Rutul R Chief Operating Officer August 3, 2026 Sell pre-set plan 33,772 $6.50 $219,518
Thomasian Harry Jr. Chief Financial Officer July 31, 2026 Sell pre-set plan 100,000 $6.06 $606,000
Thomasian Harry Jr. Chief Financial Officer July 1, 2026 Sell pre-set plan 171,429 $5.53 $948,002
Sabzevari Helen President and CEO June 29, 2026 Sell pre-set plan 346,836 $5.89 $2M
Shah Rutul R Chief Operating Officer June 29, 2026 Sell pre-set plan 42,924 $5.85 $251,105
Thomasian Harry Jr. Chief Financial Officer June 29, 2026 Sell pre-set plan 28,571 $5.78 $165,140

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 12, 2026 estimated from the company's past filing pattern, not announced

  • August 4, 2026
  • May 13, 2026
  • March 25, 2026
  • November 13, 2025
  • May 14, 2025
  • March 19, 2025

Recent SEC filings

Data status

When each part of this page on Precigen, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Precigen, Inc. in brief

What does Precigen, Inc. do?
Precigen, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Precigen, Inc.'s stock ticker?
Precigen, Inc. trades under the ticker PGEN on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Precigen, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Patient Capital Management, LLC, Blackrock, Inc. and State Street Corp. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Precigen, Inc.'s market cap?
On December 31, 2025, Precigen, Inc.'s market capitalisation was about $1.3B and net debt of $69.8M. Market figures come from third-party market data and may be delayed.
How much debt does Precigen, Inc. have?
Precigen, Inc.'s debt-to-equity ratio is 215.4%, from its latest balance sheet (167.6% five years earlier). The financial health section below sets out its other solvency checks.
Who are Precigen, Inc.'s competitors?
In our Biotechnology peer group, the companies closest to Precigen, Inc. are Janux Therapeutics, Inc., Crispr Therapeutics AG, Scynexis Inc, Abeona Therapeutics Inc. and Celularity Inc. The side-by-side comparison below sets their revenue, margins and growth against Precigen, Inc.'s.
Are insiders buying or selling Precigen, Inc. stock?
Over the last 12 months, Precigen, Inc.'s directors and officers reported 1 open-market purchases and 40 sales on Form 4. The insider trading page charts every trade.
When is Precigen, Inc.'s next earnings date?
Around November 4, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Precigen, Inc. announces its own schedule.